A new study of over 32,000 US veterans has found that the longer people stay on medications for opioid use disorder (buprenorphine, methadone, or extended-release naltrexone), the greater the probability of short- and medium-term survival. This benefit continues to increase for at least four years of ongoing treatment, considerably longer than most patients currently stay in treatment.
This article was originally published on MedicalXpress.com

